Calquence (Acalabrutinib)

Calquence (Acalabrutinib) Product Description

Calquence, known by its generic name Acalabrutinib, is a targeted therapy used in the treatment of certain types of blood cancers, including mantle cell lymphoma (MCL) and chronic lymphocytic leukemia (CLL). As a Bruton’s tyrosine kinase (BTK) inhibitor, Calquence works by blocking signals that lead to the growth and survival of cancer cells.

How Calquence Works

Calquence selectively inhibits BTK, which plays a crucial role in the signaling pathways that promote the survival and proliferation of malignant B cells. By inhibiting this pathway, Calquence helps to reduce tumor growth and may improve patient outcomes.

Indications

Calquence is indicated for:

• Patients with mantle cell lymphoma who have received at least one prior therapy.
• Patients with chronic lymphocytic leukemia who have received at least one prior therapy or are treatment-naive.

Administration

Calquence is administered orally, typically taken twice daily. It can be taken with or without food, and patients should follow their healthcare provider's instructions regarding dosage and duration of treatment.

Potential Side Effects

Common side effects of Calquence may include:

• Headache
• Diarrhea
• Fatigue
• Nausea
• Increased risk of infections

Patients should report any severe side effects or signs of infection to their healthcare provider promptly.

Drug Interactions

Calquence may interact with other medications. Patients should inform their healthcare provider of all medications they are taking, including over-the-counter drugs and supplements, to avoid potential interactions.

Conclusion

Calquence offers a promising treatment option for patients with specific types of blood cancers. Its targeted approach aims to improve efficacy while minimizing side effects. Always consult with a healthcare provider for personalized medical advice and treatment plans.